PARIS — Two post hoc analyses of the DIAMOND trial presented at the Euretina congress showed comparable efficacy of OCS-01 in phakic and pseudophakic eyes as well as in treatment-naive vs. previously treated patients.
OCS-01 (Oculis) is an investigational eye drop for the treatment of diabetic macular edema . The proprietary Optireach technology allows a high concentration (15 mg/mL) of the active ingredient, dexamethasone, to penetrate into the posterior segment of the eye.
{{VIDEO}}
“The treatment is administered in a very simple way,” Patricio G. Schlottmann, MD, said.
DIAMOND is a phase 2/3